<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;RB1&lt;/i&gt;
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        RB1
       </i>
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         RB1
        </i>
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jesse L Berry, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jaclyn A Biegel, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne Slavotinek, MBBS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H605392366">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Loss of functional retinoblastoma (Rb1) protein predisposes to retinoblastoma in the developing retina.
        </p>
        <p>
         Genetic variants in the
         <em>
          RB1
         </em>
         gene can be somatically acquired or carried in the germline. Testing DNA from peripheral blood lymphocytes (and including tumor tissue when available) is performed in all children with retinoblastoma.
        </p>
        <p>
         This monograph summarizes interpretation of germline
         <em>
          RB1
         </em>
         analysis. Other considerations
         <em>
         </em>
         such as somatic
         <em>
          RB1
         </em>
         mutations in cancer are discussed separately [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Resources'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2812819213">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H1723485402">
         <span class="h2">
          How to read the report
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tables summarize genetic testing caveats  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 1
         </a>
         ) and provide a glossary of selected terms  (
         <a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Pathogenicity is classified into five categories, from pathogenic to benign. The classification reflects the confidence that the variant is associated with disease, not disease likelihood or severity.
        </p>
        <p>
         Caveats specific to
         <em>
          RB1
         </em>
         testing include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Likelihood of germline variant
         </strong>
         – Children with bilateral retinoblastoma are presumed to have a germline pathogenic variant in
         <em>
          RB1
         </em>
         . Children with unilateral retinoblastoma have a 15 percent chance of carrying a germline
         <em>
          RB1
         </em>
         variant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           RB1
          </em>
         </strong>
         <strong>
          gene versus chromosomal region
         </strong>
         –
         <em>
          RB1
         </em>
         function can be disrupted by a variant within the gene or loss of a large chromosome 13 segment that includes
         <em>
          RB1
         </em>
         , such as 13q deletion syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other types of testing besides DNA sequencing should be considered, such as  (
         <a class="graphic graphic_table graphicRef88522" href="/z/d/graphic/88522.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fluorescence in situ hybridization (FISH) f
         <em>
          or RB1
         </em>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Quantitative DNA analysis of coding exons of
         <em>
          RB1
         </em>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Whole genome chromosomal microarray
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Each method may miss specific types of variants, especially if germline mosaicism is present. Review with a genetics expert or ocular oncologist is important to ensure appropriate and complete testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          De novo versus inherited
         </strong>
         – Most germline
         <em>
          RB1
         </em>
         variants arise de novo (new in the affected individual) rather than being inherited from a parent. A negative family history cannot be used to exclude a germline
         <em>
         </em>
         variant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mosaic variants
         </strong>
         – Germline variants are typically present in all cells of the body. Rarely, a mutation occurs later in development and is only present in a portion of cells, termed a mosaic variant. Mosaicism is a de novo mechanism; parents and siblings do not require testing. However, the variant may be passed on to the individual's offspring.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor testing
         </strong>
         – Clinical guidelines specify genetic testing of the tumor when an eye has been removed (enucleated) as part of treatment. This is seldom possible since most patients are treated with a globe-sparing approach.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liquid biopsy
         </strong>
         – Advances in molecular diagnostics have facilitated detection of circulating tumor DNA to identify tumor-derived
         <em>
          RB1
         </em>
         mutations in other fluids such as blood or aqueous humor [
         <a href="#rid2">
          2-4
         </a>
         ]. Laboratories certified by the College of American Pathologists (CAP) or Clinical Laboratory Improvement Amendments (CLIA) are beginning to use these tests.
        </p>
        <p>
        </p>
        <p>
         When tumor tissue or tumor DNA from a liquid biopsy source is available, genetic testing can ensure that biallelic inactivating variants in
         <em>
          RB1
         </em>
         are detected, including a possible germline variant. Negative germline testing when the tumor variant(s) are uncharacterized must be interpreted with caution due to a small risk (&lt;1 percent) of a false negative test.
        </p>
        <p class="headingAnchor" id="H483818572">
         <span class="h2">
          <i>
           RB1
          </i>
          genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          RB1
         </em>
         was the first tumor suppressor to be molecularly defined [
         <a href="#rid5">
          5
         </a>
         ]. The pRB protein is a target of cyclin dependent kinases that regulate the G1 to S cell cycle transition and protect cells from replicating DNA prematurely.
        </p>
        <p>
         <em>
          RB1
         </em>
         can be inactivated by single nucleotide variants, small insertions or deletions (in/dels), intragenic deletions or duplications, or whole gene deletions involving
         <em>
          RB1
         </em>
         or a larger region of chromosome 13 (13q deletion). Promoter hypermethylation can also occur.
        </p>
        <p>
         Inactivation of both
         <em>
          RB1
         </em>
         alleles (one from each parent) is generally required for tumorigenesis. Individuals with heritable retinoblastoma are born with one
         <em>
          RB1
         </em>
         variant in all or many of their cells; somatic inactivation of the second allele in developing retinal tissue (a "second hit") leads to retinoblastoma, which can be unilateral, bilateral, or trilateral (bilateral retinoblastoma plus an intracranial tumor of similar histology) [
         <a href="#rid5">
          5
         </a>
         ]. In sporadic retinoblastoma, both hits occur in the retina. Biallelic germline
         <em>
          RB1
         </em>
         inactivation is incompatible with life.
        </p>
        <p>
         Approximately 10 percent of individuals with retinoblastoma have a germline
         <em>
          RB1
         </em>
         variant and a positive family history (familial retinoblastoma); another 30 percent have a de novo germline mutation. The remaining 60 percent have sporadic disease, with both
         <em>
          RB1
         </em>
         alleles inactivated somatically.
        </p>
        <p class="headingAnchor" id="H3675599214">
         <span class="h2">
          Heritable retinoblastoma
         </span>
        </p>
        <p class="headingAnchor" id="H470022585">
         <span class="h3">
          Retinoblastoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinoblastoma is a malignant tumor of the developing retina. Untreated, it can destroy the eye, invade the orbit and nasal cavity, and metastasize to lung, bone, liver, or brain. Survival is &gt;95 percent with treatment if the tumor is confined to the eye; eye preservation depends on disease stage. Prognosis decreases dramatically with extra-ocular disease. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Natural history'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a child with a germline pathogenic variant in
         <em>
          RB1
         </em>
         , the likelihood of developing retinoblastoma is 95 to 100 percent. The risk of ipsilateral and contralateral tumors is high. Tumors develop in infancy or early childhood, often before one year and nearly always before seven years [
         <a href="#rid6">
          6-8
         </a>
         ]. Retinomas (benign tumors that spontaneously regress) are extremely rare. Malignant tumors (melanoma, several types of sarcoma) can develop later. (See
         <a class="local">
          'Extraocular tumors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Knowing whether germline disease is present is paramount for risk assessment, surveillance, and screening of relatives.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All children with retinoblastoma with a positive family history and/or bilateral (or trilateral) disease will have a germline pathogenic variant in
         <em>
          RB1
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Up to 15 percent of children with
         <strong>
          unilateral disease
         </strong>
         also harbor a germline
         <em>
          RB1
         </em>
         variant. A common misperception that these individuals cannot harbor a germline variant is incorrect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We recommend genetic testing in all individuals with retinoblastoma, although some insurance policies will only cover testing in children with unilateral disease.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2894689634">
         <span class="h3">
          Extraocular tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of extraocular tumors in heritable retinoblastoma is approximately 0.5 to 1 percent per year (20 percent risk by age 20 years) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pineoblastoma (a pineal gland tumor), sometimes called "trilateral" retinoblastoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcomas
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Osteosarcoma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rhabdomyosarcoma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leiomyosarcoma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Angiosarcoma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fibrosarcoma of soft tissue
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Liposarcoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Melanoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast, skin, and lung cancer
        </p>
        <p>
        </p>
        <p>
         Pineoblastoma may be diagnosed concurrently or within a few years of retinoblastoma. Other tumors generally occur later; risk may be further increased by exposure to ionizing radiation or ultraviolet light.
        </p>
        <p class="headingAnchor" id="H3690620928">
         <span class="h1">
          CANCER TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following general principles may apply; individual decisions are made by an ocular oncologist and multidisciplinary team who can fully evaluate the patient and determine the best treatment
         <em>
         </em>
         [
         <a href="#rid8">
          8,9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retinoblastoma
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early detection is essential; retinoblastoma that has spread outside the globe has a much worse prognosis than disease confined to the intraocular space [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/107561.html" rel="external">
          "Retinoblastoma: Treatment and outcome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Multidisciplinary involvement is used for planning and coordination of care, evaluation of extent of disease, and optimal therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment that optimizes long-term patient survival is paramount. Saving the eye and preserving vision are secondary and tertiary priorities.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Radiation therapy is avoided if possible as it increases the risk of secondary tumors. Radiation is generally reserved for relapsed disease in the remaining eye and is now infrequently used.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For heritable retinoblastoma, lifelong follow-up is required to assess for complications of therapy, ensure adequate surveillance for other cancers, and provide appropriate genetic counseling and psychosocial care. (See
         <a class="local">
          'Cancer surveillance and risk reduction'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extraocular tumors
         </strong>
         – Management should be coordinated by an expert in the specific tumor type (sarcoma expert, melanoma expert). Specialists should be informed that the individual has a germline pathogenic variant in
         <em>
          RB1
         </em>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3437073481">
         <span class="h1">
          CANCER SURVEILLANCE AND RISK REDUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         At-risk individuals should undergo ophthalmic surveillance for retinoblastoma and imaging for pineoblastoma during early childhood, as summarized in the table  (
         <a class="graphic graphic_table graphicRef130842" href="/z/d/graphic/130842.html" rel="external">
          table 4
         </a>
         ). This is often best done as part of a multisubspecialty team with expertise in retinoblastoma management.
        </p>
        <p>
         The surveillance approach depends on the level of risk, which is based on genetic testing and/or family history.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dilated funduscopic examination is performed starting at birth, with intervals and need for examination under anesthesia based on risk category, which is based on a 2018 consensus report from the American Association of Ophthalmic Oncologists and Pathologists [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High risk
         </strong>
         – Monthly until 12 months (some under anesthesia), increasing intervals until 7 years, and every 1 to 2 years thereafter.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intermediate risk
         </strong>
         – Monthly until 3 months (some under anesthesia), increasing intervals until 7 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low risk
         </strong>
         – Monthly until 3 months (none under anesthesia unless an abnormality is found), increasing intervals until 7 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain magnetic resonance imaging (MRI) including pineal images in patients with a germline
         <em>
          RB1
         </em>
         variant is started at three months and continued every six months to age three to five years, depending on the center. MRI is preferred over computed tomography (CT) to avoid radiation exposure. Some centers (in Europe and other regions) omit brain MRI.
        </p>
        <p>
        </p>
        <p>
         There are no routine imaging recommendations for older children and adults, for whom imaging confers risks and burdens and has not been shown to improve outcomes. However, regular examinations are important (including full skin), and the threshold should be low for evaluating symptoms or findings that could suggest a malignancy, such as unexplained pain or swelling, ideally performed by a cancer survivorship clinic.
        </p>
        <p>
         Cancer risk reduction includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintaining a healthy diet rich in vegetables
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding radiation exposure, including diagnostic imaging and ultraviolet light
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding DNA damaging agents such as cigarette smoke and alcohol
        </p>
        <p>
        </p>
        <p>
         Individuals who have a germline variant of uncertain significance (VUS) in
         <em>
          RB1
         </em>
         are treated based on their personal and family history. The variant should be re-evaluated periodically to determine if its significance has been clarified based on additional research.
        </p>
        <p>
         Individuals with unilateral retinoblastoma who lack a germline
         <em>
          RB1
         </em>
         alteration can be spared additional surveillance for retinoblastoma and associated tumors and do not require preconception counseling or testing of their children, with the caveats that without tumor testing there is a small (&lt;1 percent) risk of a false negative test, and offspring should have ophthalmic screening.
        </p>
        <p class="headingAnchor" id="H2470393227">
         <span class="h1">
          RELATIVES AND PRECONCEPTION COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a child is diagnosed with heritable retinoblastoma, first-degree relatives should be tested for that child's
         <em>
          RB1
         </em>
         variant, as depicted in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130844" href="/z/d/graphic/130844.html" rel="external">
          algorithm 1
         </a>
         ). A heritable syndrome due to a germline pathogenic variant in RB1 may be seen in individuals with unilateral, bilateral, or trilateral retinoblastoma. (See
         <a class="local">
          'Retinoblastoma'
         </a>
         above.)
        </p>
        <p>
         The parents can be evaluated by an ophthalmologist for retinomas (benign retinal tumors) but should undergo genetic testing for the variant regardless of ophthalmologic findings.
        </p>
        <p>
         If a parent carries the same
         <em>
          RB1
         </em>
         variant as the affected child, all of the child's siblings should be tested. The parent's siblings should consider testing as well.
        </p>
        <p>
         If a familial
         <em>
          RB1
         </em>
         variant is known and a relative tests negative for that variant, they can be reassured that they are not at increased risk for heritable retinoblastoma.
        </p>
        <p>
         For individuals with a germline
         <em>
          RB1
         </em>
         variant, preconception counseling is appropriate to review the risk that a future child will be affected and to discuss reproductive options such as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In vitro fertilization (IVF) with preimplantation genetic testing (PGT)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Donor gametes (egg or sperm)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adoption
        </p>
        <p>
        </p>
        <p>
         Individuals who do not use PGT or donor gametes may have prenatal testing (chorionic villus sampling or amniocentesis). Others may pursue genetic testing once the child is born.
        </p>
        <p>
         A child who tests positive for the familial variant is at risk for retinoblastoma; in some cases, tumors can develop before birth. Ophthalmic examination is recommended as soon as possible after birth, with prenatal and postnatal care coordinated among a high-risk obstetrician, geneticist, and ocular oncologist to determine the best surveillance approach. Some specialists suggest early delivery, whereas others believe the benefits may not outweigh the risks and burdens.
        </p>
        <p class="headingAnchor" id="H2739667639">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Locating a specialist:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic counselors – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=129267" target="_blank">
          NSGC
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical geneticists – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=129267" target="_blank">
          ACMG
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Retinoblastoma treatment centers – One retinoblastoma world
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fmap.1rbw.org%2F&amp;token=3K5P00iH5mXcYwvRPFbzZn3wfjsOSr8RGAXLwBYGyEY%3D&amp;TOPIC_ID=129267" target="_blank">
          database
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         National Institutes of Health (NIH) Cancer Genetics
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=129267" target="_blank">
          Services Directory
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         UpToDate topics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Retinoblastoma – (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/107561.html" rel="external">
          "Retinoblastoma: Treatment and outcome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chromosome 13q deletion – (See
         <a class="medical medical_review" href="/z/d/html/16648.html" rel="external">
          "Microdeletion syndromes (chromosomes 12 to 22)", section on '13q14 deletion syndrome (Retinoblastoma syndrome)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reproductive options – (See
         <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">
          "Preimplantation genetic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">
          "In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">
          "Donor insemination"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2854.html" rel="external">
          "Adoption"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         National Cancer Institute – Physician data query document (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK66006%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trz2mmD0gY3gbWR%2Bj1De8CjxRNqHZ%2BMqP9AkO08b5BdeRw%3D%3D&amp;TOPIC_ID=129267" target="_blank">
          PDQ
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson DH, Mandelker D, Francis JH, et al. Retrospective Evaluation of Somatic Alterations in Cell-Free DNA from Blood in Retinoblastoma. Ophthal Sci 2021; 1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu L, Shen L, Polski A, et al. Simultaneous identification of clinically relevant RB1 mutations and copy number alterations in aqueous humor of retinoblastoma eyes. Ophthalmic Genet 2020; 41:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerrish A, Stone E, Clokie S, et al. Non-invasive diagnosis of retinoblastoma using cell-free DNA from aqueous humour. Br J Ophthalmol 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry JL, Polski A, Cavenee WK, et al. The RB1 Story: Characterization and Cloning of the First Tumor Suppressor Gene. Genes (Basel) 2019; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry JL, Lewis L, Zolfaghari E, et al. Lack of correlation between age at diagnosis and RB1 mutations for unilateral retinoblastoma: the importance of genetic testing. Ophthalmic Genet 2018; 39:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong JR, Morton LM, Tucker MA, et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol 2014; 32:3284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet 2012; 379:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skalet AH, Gombos DS, Gallie BL, et al. Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology 2018; 125:453.
          </a>
         </li>
         <li class="breakAll">
          PDQ Pediatric Treatment Editorial Board. Retinoblastoma treatment. Available at: https://www.ncbi.nlm.nih.gov/books/NBK66006/ (Accessed on October 09, 2020).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 129267 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Retrospective Evaluation of Somatic Alterations in Cell-Free DNA from Blood in Retinoblastoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32799607" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Simultaneous identification of clinically relevant RB1 mutations and copy number alterations in aqueous humor of retinoblastoma eyes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30745306" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Non-invasive diagnosis of retinoblastoma using cell-free DNA from aqueous humour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31683923" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The RB1 Story: Characterization and Cloning of the First Tumor Suppressor Gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29286867" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lack of correlation between age at diagnosis and RB1 mutations for unilateral retinoblastoma: the importance of genetic testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25185089" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22414599" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29056300" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Screening Children at Risk for Retinoblastoma: Consensus Report from the American Association of Ophthalmic Oncologists and Pathologists.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
